論文

査読有り
2016年4月1日

Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice

Arteriosclerosis, Thrombosis, and Vascular Biology
  • Emi Yakushiji
  • Makoto Ayaori
  • Takafumi Nishida
  • Kazusa Shiotani
  • Shunichi Takiguchi
  • Kazuhiro Nakaya
  • Harumi Uto-Kondo
  • Masatsune Ogura
  • Makoto Sasaki
  • Makiko Yogo
  • Tomohiro Komatsu
  • Rui Lu
  • Shinji Yokoyama
  • Katsunori Ikewaki
  • 全て表示

36
4
開始ページ
591
終了ページ
597
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1161/ATVBAHA.115.306376
出版者・発行元
Lippincott Williams and Wilkins

Objective - Oxidized products of probucol, spiroquinone and diphenoquinone, were shown to increase cell cholesterol release and plasma high-density lipoprotein (HDL) by inhibiting degradation of ATP-binding cassette transporter A1. We investigated whether these compounds enhance reverse cholesterol transport in mice. Approach and Results - Spiroquinone and diphenoquinone increased ATP-binding cassette transporter A1 protein (2.8- and 2.6-fold, respectively, P&lt
0.01) and apolipoprotein A-I-mediated cholesterol release (1.4- and 1.4-fold, P&lt
0.01 and P&lt
0.05, respectively) in RAW264.7 cells. However, diphenoquinone, but not spiroquinone, enhanced cholesterol efflux to HDL (+12%, P&lt
0.05), whereas both increased ATP-binding cassette transporter G1 protein, by 1.8- and 1.6-fold, respectively. When given orally to mice, both compounds significantly increased plasma HDL-cholesterol, by 19% and 20%, respectively (P&lt
0.05), accompanied by an increase in hepatic and macrophage ATP-binding cassette transporter A1 but not ATP-binding cassette transporter G1. We next evaluated in vivo reverse cholesterol transport by injecting RAW264.7 cells labeled with 3H-cholesterol intraperitoneally into mice. Both spiroquinone and diphenoquinone increased fecal excretion of the macrophage-derived 3H-tracer, by 25% and 28% (P&lt
0.01 and P&lt
0.05), respectively. spiroquinone/diphenoquinone did not affect fecal excretion of HDL-derived 3H-cholesterol, implying that macrophage-to-plasma was the most important step in spiroquinone/diphenoquinone-mediated promotion of in vivo reverse cholesterol transport. Finally, spiroquinone significantly reduced aortic atherosclerosis in apolipoprotein E null mice when compared with the vehicle. Conclusions - Spiroquinone and diphenoquinone increase functional ATP-binding cassette transporter A1 in both the macrophages and the liver, elevate plasma HDL-cholesterol, and promote overall reverse cholesterol transport in vivo. These compounds are promising as therapeutic reagents against atherosclerosis.

リンク情報
DOI
https://doi.org/10.1161/ATVBAHA.115.306376
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26848156
ID情報
  • DOI : 10.1161/ATVBAHA.115.306376
  • ISSN : 1524-4636
  • ISSN : 1079-5642
  • PubMed ID : 26848156
  • SCOPUS ID : 84957651065

エクスポート
BibTeX RIS